STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Meyer Losic, Florence ^a   Newman, Simon P ^b   Day, Joanna M ^b   Reed, Michael J ^b   Kasprzyk, Philip G ^c   Purohit, Atul ^b   Foster, Paul A ^d  

^a IPSEN   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Biomeasure Inc   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; STX 140; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST METASTASIS; BREAST TUMOR; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EMBRYO; FEMALE; HYPERALGESIA; LUNG METASTASIS; MOUSE; NEUROTOXICITY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PERIPHERAL NEUROPATHY; PRIMARY TUMOR; RAT; SURVIVAL TIME; THERAPY DELAY; THERMAL STIMULATION; TOXICITY TESTING; TRANSGENIC MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ESTRENES; FEMALE; HUMANS; HYPERALGESIA; LUNG NEOPLASMS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84891915811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080305     Document Type: Article

References (36)

1. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapyinduced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507-15.
2. Jared JA, Tkaczuk KH (2012) Update on taxane development: new analogs and formulations. Drug Dis Devel Ther 6:371-84.
3. Purohit A, Hejaz HA, Walden L, MacCarthy-Morrogh L, Packham G, et al. (2000) The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 85: 584-9. (Pubitemid 30075140)
4. MacCarthy-Morrogh L, Townsend PA, Purohit A, Hejaz HA, Potter BV, et al. (2000) Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 60:5441-50.
5. Day JM, Newman SP, Comninos A, Solomon C, Purohit A, et al. (2003) The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 84:317-25. (Pubitemid 36514846)
6. Newman SP, Leese MP, Purohit A, James DR, Rennie CE, et al. (2004) Inhibition of in vitro angiogenesis by 2-methoxy-and 2-ethyl-estrogen sulfamates. Int J Cancer 109:533-40. (Pubitemid 38339643)
7. Ireson CR, Chander SK, Purohit A, Parish DC, Woo LW, et al. (2004) Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiolbis- sulphamate in vivo in rodents. Br J Cancer 90:932-7. (Pubitemid 38406609)
8. Raobaikady B, Reed MJ, Leese MP, Potter BV, Purohit A (2005) Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono-and bis-3-O-sulphamates. Int J Cancer 117:150-9. (Pubitemid 41262769)
9. Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, et al. (2006) 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 28:7683-96. (Pubitemid 46033660)
10. Chander SK, Foster PA, Leese MP, Newman SP, Potter BV, et al. (2007) In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 96: 1368-76. (Pubitemid 46685788)
11. Foster PA, Ho YT, Newman SP, Kasprzyk PG, Leese MP, et al. (2008) 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat 111;251-260.
12. Newman SP, Foster PA, Ho YT, Day JM, Raobaikady B, et al. (2007) The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancer. Br J Cancer 97:1673-82. (Pubitemid 350249364)
13. Newman SP, Foster PA, Stengel C, Day JM, Ho YT, et al. (2008) STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 14:597-606. (Pubitemid 351226130)
14. Foster PA, Newman SP, Leese MP, Bernetiere S, Diolez C, et al. (2008) A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer. Anticancer Res 28:577-81. (Pubitemid 351578896)
15. Foster PA, Stengel C, Ali T, Leese MP, Potter BV, et al. (2008) A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res 28:1483-91. (Pubitemid 351892920)
16. Tagg SL, Foster PA, Leese MP, Potter BV, Reed MJ, et al. (2008) 2-methoxyestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential new treatment for breast cancer. Br J Cancer 99:1842-8.
17. Stengal C, Newman SP, Leese MP, Potter BV, Reed MJ, et al. (2010) Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102:316-24.
18. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, et al. (2000) The C3(1)SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19:1020-7. (Pubitemid 30153785)
19. Becher OJ, Holland EC (2007) Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66:3355-59.
20. Radiloff DR, Rinella ES, Threadgill DW (2008) Modeling cancer patient populations in mice: complex genetic and environmental factors. Drug Disc Today 4:83-88. (Pubitemid 351409231)
21. Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, et al. (2005) Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24:790-800. (Pubitemid 40216087)
22. Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, et al. (2002) Inhibition of the mammary carcinoma angiogenic swith in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 101:224-34. (Pubitemid 34970889)
23. Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, et al. (2001) 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor intiation in C3(1)SV40 T/tantigen transgenic mice. Cancer Res 61:7449-55. (Pubitemid 32995033)
24. Hardman WE, Ion G, Akinsete JA, Witte TR (2011) Dietary walnut suppressed mammary gland tumorigenesis in the C(3)1 TAg mouse. Nutr Cancer 63:960-70.
25. Huh JI, Calvo A, Charles R, Green JE (2006) Distince tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression. Cancer Res 66:3495-3503.
26. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-77.
27. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, et al. (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17:163-70. (Pubitemid 29335443)
28. Sandkühler J (2009) Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 89:707-58.
29. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
30. Russnes HG, Navin N, Hicks J, Borresen-Dale AL (2011) Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 121:3810-3818.
31. Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MF, et al. (2006) The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 66:324-30. (Pubitemid 43166039)
32. Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, et al. (2007) Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther 6:1717-25. (Pubitemid 351590306)
33. Suárez F, Jockovich ME, Hernandez E, Feuer W, Parel JM, et al. (2007) Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma. Invest Opthalmol Vis Sci 48:3437-40. (Pubitemid 351261076)
34. Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapyinduced peripheral neuropathy: prevention and treatment. Clin Pharacol Ther 90:377-387.
35. Smith SB, Crager SE, Mogil JS (2004) Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred strains. Life Sci 7:2593-604. (Pubitemid 38369356)
36. Van S, Das SK, Wang X, Feng Z, Jin Y, et al. (2010) Synthesis, characterisation, and biological evaluation of poly(L-y-glutamyl-glutamine)- paclitaxel nanoconjugates. Int J Nanomedicine 5:825-37.